Last reviewed · How we verify
GLS-1027
At a glance
| Generic name | GLS-1027 |
|---|---|
| Sponsor | GeneOne Life Science, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLS-1027 CI brief — competitive landscape report
- GLS-1027 updates RSS · CI watch RSS
- GeneOne Life Science, Inc. portfolio CI